Table 5.
Multivariate analysis with SUVmax, MTV3.5, and TLG3.5 for RFS.
| RFS model with SUVmax | RFS model with MTV3.5 | RFS model with TLG3.5 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| P | Hazard ratio | 95% CI | P | Hazard ratio | 95% CI | P | Hazard ratio | 95% CI | |
| Sex | 0.267 | 1.386 | 0.778–2.467 | 0.230 | 1.425 | 0.800–2.539 | 0.331 | 1.327 | 0.750–2.349 |
| Age ≥66 | 0.282 | 1.421 | 0.749–2.695 | 0.366 | 1.340 | 0.711–2.526 | 0.380 | 1.329 | 0.704–2.510 |
| CA19-9 ≥276.5 | 0.058 | 1.748 | 0.982–3.112 | 0.040* | 1.829 | 1.030–3.250 | 0.060 | 1.936 | 0.978–3.084 |
| Resectability, BR | 0.098 | 1.651 | 0.912–2.988 | 0.219 | 1.435 | 0.807–2.553 | 0.187 | 1.473 | 0.187–0.828 |
| SUVmax ≥4.87 | 0.041* | 1.797 | 1.026–3.149 | ||||||
| MTV3.5 ≥2.46 | 0.030* | 1.849 | 1.062–3.220 | ||||||
| TLG3.5 ≥9.99 | 0.128 | 1.527 | 0.886–2.632 | ||||||
BR, borderline resectable; CA19-9, cancer antigen 19-9; CI, confidence interval; DSS, disease-specific survival; MTV, mean tumor volume; RFS, recurrence free survival; SD, standard deviation; SUVmax, maximum standardized uptake value; TLG, total lesion glycolysis.
*P < 0.05.